Browse

Metastatectomy prior to immunochemotherapy for metastatic renal cell carcinoma

DC Field Value Language
dc.contributor.authorLee, Sang Eun-
dc.contributor.authorKwak, Cheol-
dc.contributor.authorByun, Seok-Soo-
dc.contributor.authorGill, Myung Chul-
dc.contributor.authorChang, In Ho-
dc.contributor.authorKim, Yong June-
dc.contributor.authorHong, Sung Kyu-
dc.date.accessioned2009-10-21T05:54:45Z-
dc.date.available2009-10-21T05:54:45Z-
dc.date.issued2006-
dc.identifier.citationUrol Int 2006;76:256-263en
dc.identifier.issn0042-1138 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16601390-
dc.identifier.urihttp://hdl.handle.net/10371/10589-
dc.description.abstractINTRODUCTION: We reviewed our experiences in performing cytoreductive metastatectomy before initiating systemic immunochemotherapy and tried to investigate potential prognostic factors for such an approach. PATIENTS AND METHODS: A retrospective analysis of 57 patients who received interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy for metastatic renal cell carcinoma was conducted. Before undergoing immunochemotherapy, 20 of the 57 patients had received metastatectomy along with nephrectomy (metastatectomy group) and the other 37 nephrectomy alone (non-metastatectomy group). RESULTS: The metastatectomy group demonstrated median disease-specific and progression-free survival of 23 and 13 months, respectively. The patients in the metastatectomy group were identified as having a better performance status and primarily demonstrating pulmonary metastasis compared with those in the non-metastatectomy group. As assessed in the metastatectomy group, factors such as the number of metastatic lesions, completeness of metastatectomy, and location of metastatic lesions (lung only vs. others) were observed to be significantly associated with overall survivals on univariate analysis. CONCLUSIONS: Metastatectomy may still play a significant therapeutic role for metastatic renal cell carcinoma even in the era of immunochemotherapy as part of a multidisciplinary treatment approach in a selected group of patients in adequate general condition who have pulmonary-limited metastasis that can be completely resected.en
dc.language.isoenen
dc.publisherKargeren
dc.subjectMetastatic renal cell carcinomaen
dc.subjectMetastatectomyen
dc.subjectInterleukin-2en
dc.subjectInterferon-en
dc.subject5-Fluorouracilen
dc.titleMetastatectomy prior to immunochemotherapy for metastatic renal cell carcinomaen
dc.typeArticleen
dc.contributor.AlternativeAuthor이상은-
dc.contributor.AlternativeAuthor곽철-
dc.contributor.AlternativeAuthor변석수-
dc.contributor.AlternativeAuthor길명철-
dc.contributor.AlternativeAuthor장인호-
dc.contributor.AlternativeAuthor김용준-
dc.contributor.AlternativeAuthor홍성규-
dc.identifier.doi10.1159/000091630-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Urology (비뇨기과학전공)Journal Papers (저널논문_비뇨기과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse